Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CollaGenex has entered into a definitive agreement to acquire all the shares of SansRosa Pharmaceutical Development the owner of various patent applications covering treatments for rosacea and other skin disorders.
Subscribe to our email newsletter
CollaGenex will make an initial payment of $750,000 for 51% of the shares of SansRosa. The remaining shares will be purchased upon the achievement of various milestones.
If all milestones are achieved and a patented product is developed and approved for sale, CollaGenex will pay the shareholders of SansRosa an additional $4-$6 million. CollaGenex will be solely responsible for product and clinical development.
“There are currently no effective treatments for the redness associated with rosacea and certain other dermatological conditions,” said Colin Stewart, president and CEO of CollaGenex. “If successfully developed and approved, a topical product based on SansRosa’s technology would complement our existing pipeline, including Oracea, which is currently under review by the FDA.”